Patents Assigned to Noscira, S.A.
-
Publication number: 20140011835Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or prophylaxis of a neurodegenerative or hematological disease or condition, their use as a medicament, especially for treating a neurodegenerative or hematological disease or condition, and a pharmaceutical composition comprising the compounds.Type: ApplicationFiled: September 15, 2013Publication date: January 9, 2014Applicant: Noscira, S.A.Inventors: Ana MARTINEZ GIL, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
-
Publication number: 20140005195Abstract: The present invention relates to novel bipyridine sulfonamide derivatives of formula (I) and their use for the treatment and/or prophylaxis of a neurodegenerative disease or condition, particularly Alzheimers disease (AD), a cardiovascular disease or a pathology involving ischemia. Additionally, processes for preparing such derivatives5 and pharmaceutical compositions comprising them are provided.Type: ApplicationFiled: November 21, 2011Publication date: January 2, 2014Applicant: Noscira, S.A.Inventors: Francisco Palomo Nicolau, Jorge Sánchez-Quesada, Javier López Ogalla, Félix Hernández Juan, Javier Villasante Prieto, Miguel Medina Padilla, Ana Fuertes Huerta, Juan Manuel Dominguez Correa, Susan Herrero Santos, Mercedes Alonso Cascón
-
Patent number: 8592446Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds.Type: GrantFiled: June 11, 2008Date of Patent: November 26, 2013Assignee: Noscira, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
-
Patent number: 8158661Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.Type: GrantFiled: April 22, 2009Date of Patent: April 17, 2012Assignee: Noscira, S.A.Inventors: Miguel Medina Padilla, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Ana Martinez Gil, Gema Panizo Del Pliego, Ana Fuertes Huerta, Maria Jose Perez Puerto
-
Publication number: 20110306631Abstract: The present invention relates to a new family of triple substituted phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition or cancer, their use as a medicament, especially for treating a neurodegenerative or haematological disease or condition or cancer, and a pharmaceutical composition comprising the compounds.Type: ApplicationFiled: December 10, 2009Publication date: December 15, 2011Applicant: NOSCIRA, S.A.Inventors: Miguel Medina Padilla, Ana Castro Morera, Jorge Sánchez-Quesada, Esther García Palomero, Mercedes Alonso Cascón, Susana Herrero Santos, Marta Vela Ruíz, Paola Usán Egea, Ana Luisa Rodríguez Villanueva
-
Publication number: 20110144148Abstract: The invention provides compounds of formula: which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the ?-amyloid aggregation properties by binding simultaneously to the catalytic and peripheral AChE sites. They are useful in the treatment of AChE mediated diseases, such as the Alzheimer's disease.Type: ApplicationFiled: February 18, 2011Publication date: June 16, 2011Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Isabel Dorronsoro Diaz, Laura Rubio Arrieta, Diana Alonso Gordillo, Ana Fuertes Huerta, Susana Morales-Alcelay, Maria Del Monte Millan, Esther Garcia Palomero, Paola Usan Egea, Celia De Austria, Miguel Medina Padilla, Pilar Munoz Ruiz
-
Publication number: 20110092591Abstract: The present invention is related to a family of phenyl-prenyl derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the compounds of formula (I) for medical use, particularly for the use for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder, and to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.Type: ApplicationFiled: February 6, 2009Publication date: April 21, 2011Applicant: NOSCIRA S.A.Inventors: Javier Lopez Ogalla, Pilar Munoz Ruiz, Diana Alonso Gordillo, Miguel Medina Padilla, Esther Garcia Palomero, Ana Martinez Gil, Ana Castro Morera
-
Patent number: 7910739Abstract: The invention provides compounds of formula: which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the ?-amyloid aggregation properties by binding simultaneously to the catalytic and peripheral AChE sites. They are useful in the treatment of AChE mediated diseases, such as the Alzheimer's disease.Type: GrantFiled: July 9, 2004Date of Patent: March 22, 2011Assignee: Noscira, S.A.Inventors: Ana Martinez Gil, Isabel Dorronsoro Diaz, Laura Rubio Arrieta, Diana Alonso Gordillo, Ana Fuertes Huerta, Susana Morales-Alcelay, Maria Del Monte Millan, Esther Garcia Palomero, Paola Usan Egea, Celia De Austria, Miguel Medina Padilla, Pilar Munoz Ruiz
-
Publication number: 20100267827Abstract: The present invention is related to a family of phenyl-prenyl-ether derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or 5 Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.Type: ApplicationFiled: August 1, 2007Publication date: October 21, 2010Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Pilar Munoz Ruiz, Javier Lopez Ogalla, Laura Rubio Arrieta, Esther Garcia Palomero, Pablo Garcia Fernandez, Celia De Austria De Luque, Elena Delgado Hernandez, Paola Usan Egea, Rita Valenzuela Liminana, Jorge Sanchez-Quesada
-
Publication number: 20100240692Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds.Type: ApplicationFiled: June 11, 2008Publication date: September 23, 2010Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
-
Publication number: 20100041665Abstract: The present invention is related to a family of N-phenyl-prenylamine derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.Type: ApplicationFiled: August 1, 2007Publication date: February 18, 2010Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Pilar Munoz Ruiz, Javier Lopez Ogalla, Esther Garcia Palomero, Celia De Austria De Luque, Paola Usan Egea, Rita Valenzuela Liminana, Pablo Garcia Fernandez, Elena Delgado Hernandez, Daniel Ignacio Perez Fernandez
-
Publication number: 20090233971Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.Type: ApplicationFiled: April 22, 2009Publication date: September 17, 2009Applicant: Noscira, S.A.Inventors: Miguel Medina Padilla, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Ana Martinez Gil, Gema Panizo del Pliego, Ana Fuertes Huerta, Maria Jose Perez Puerto
-
Publication number: 20090221647Abstract: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I), for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.Type: ApplicationFiled: April 27, 2007Publication date: September 3, 2009Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Ester Martin Aparicio, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Maria Del Monte Millan
-
Publication number: 20090192204Abstract: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I) for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.Type: ApplicationFiled: April 27, 2007Publication date: July 30, 2009Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Ester Martin Aparicio, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Maria Del Monte Millan
-
Patent number: 7531561Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.Type: GrantFiled: April 5, 2005Date of Patent: May 12, 2009Assignee: Noscira, S.A.Inventors: Miguel Medina Padilla, Mercedes Alonso Cascón, Isabel Dorronsoro Díaz, Ana Martínez Gil, Gema Panizo del Pliego, Ana Fuertes Huerta, María José Pérez Puerto